Laboratory of Neurosciences de Brest, University of Bretagne Occidentale, Brest, France.
Acta Paediatr. 2013 Jun;102(6):e288-90. doi: 10.1111/apa.12235.
We report that daily administration of the diuretic NKCC1 chloride co-transporter, bumetanide, reduces the severity of autism in a 10-year-old Fragile X boy using CARS, ADOS, ABC, RDEG and RRB before and after treatment. In keeping with extensive clinical use of this diuretic, the only side effect was a small hypokalaemia. A double-blind clinical trial is warranted to test the efficacy of bumetanide in FRX.
This single case report showed an improvement of the scores of each test used after 3 months of treatment. Double-blind clinical trials are warranted to test the efficacy of bumetanide in FRX.
我们报告称，使用 CARS、ADOS、ABC、RDEG 和 RRB，每天给予利尿剂 NKCC1 氯离子共转运蛋白布美他尼治疗，可降低 10 岁脆性 X 男孩自闭症的严重程度，且在治疗前后均如此。鉴于该利尿剂的广泛临床应用，唯一的副作用是轻度低钾血症。有必要进行双盲临床试验来测试布美他尼在 FRX 中的疗效。
这项单病例报告显示，治疗 3 个月后，每个使用的测试的评分都有所改善。有必要进行双盲临床试验来测试布美他尼在 FRX 中的疗效。
